Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexvax2 SQ vs ID in Celiac Disease
NCT03543540Phase 1Completed
- Sponsor
- ImmusanT
- Start
- May 2018
- Primary completion
- Sep 2018
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nexvax2 in celiac disease (4 arms), sponsored by ImmusanT. Primary endpoints: Safety of Nexvax 2 administered subcutaneously at 7 weeks and Evaluate bioavailability of the constituents of Nexvax2 after SQ versus intradermal (ID) administration at 7 weeks. Started May 2018; status: completed.
02
Drugs
nexvax2
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT03543540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03543540.